Abstract
Human dialysable Transfer Factor (TFd) extracted from lymphocytes of patients with transitional cell carcinoma of bladder (TCCB) was replicated in culture by lymphoblastoid cell lines. The effectiveness of two such TFdLs produced in vitro in transferring sensitivity to TCCB was assessed in the lymphocyte migration test (LMT) using formalin-treated TCCB cells as antigen. The results, showed that one TFdL transferred sensitivity in 5/14 cases and the other in 12/15, not only to leucocytes of healthy individuals but also to leucocytes of TCCB patients. Preliminary results showing an in vivo transfer of sensitivity are discussed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Pizza, G., Viza, D., Boucheix, C. et al. In vitro production of a transfer factor specific for transitional-cell carcinoma of the bladder. Br J Cancer 33, 606–611 (1976). https://doi.org/10.1038/bjc.1976.98
Issue Date:
DOI: https://doi.org/10.1038/bjc.1976.98
This article is cited by
-
Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy
Biotherapy (1996)
-
A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer
Biotherapy (1996)
-
In vitro studies during long term oral administration of specific transfer factor
Biotherapy (1996)
-
Inhibition or augmentation of PHA-induced lymphocyte transformation by factors of cultured lymphoblastoid cell lines
Experientia (1979)
